-
First-in-human Phase 1a Study to Assess Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending doses of SB-0110 after Oral Administration in Healthy Subjects
… (PD), it has a debilitating on-target side effect of dyskinesia. An optimal PD therapy would selectively activate … of dopamine receptors while avoiding those that induce dyskinesia. Using machine learning algorithms developed by …
-
Breaking News: Addex Therapeutics Announces Reorganization to Focus on Clinical Pipeline
February 8, 2013
… Development of their dyskinesia drug continues Michael J. Fox Foundation (MJFF) … to the development of dipraglurant as a treatment for dyskinesia in Parkinson’s disease. “The data and partnering …
-
Addex Therapeutics Awarded $1 MM Grant from The Michael J. Fox Foundation for Parkinson's Research
March 19, 2013
… for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID). One-third of people with PD develop … a longstanding issue with the treatment of their disease." Dyskinesias are the uncontrollable and disruptive movements …
-
Addex Adds It Up for Parkinson's Patients
March 21, 2012
… needs for those living with Parkinson’s disease today — dyskinesia. Swiss biotech Addex Therapeutics announced … in Parkinson's disease. But levodopa can also lead to dyskinesia, the uncontrollable movements that are a …
-
Omar S. Mabrouk, PhD
… therapeutics for Parkinson’s disease and levodopa-induced dyskinesia. Dr. Mabrouk develops innovative techniques to … of Michigan. Dr. Mabrouk is also recipient of a 2013 Dyskinesia Challenge grant award from The Michael J. Fox …
-
Another Drug for Parkinson's Gets Approval
March 8, 2018
… in early Parkinson's. But doctors often prescribe it for dyskinesia (involuntary, uncontrolled movements) even though … once-a-day formulation is FDA-approved for the treatment of dyskinesia, “off” time (when symptoms are not controlled) or …